Progen. Co., Ltd.
Clinical trials sponsored by Progen. Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New diabetes shot aims to beat semaglutide in early trial Results expected Sep 2026 (estimated)
- Could a monthly shot replace weekly diabetes injections? Results expected May 2027 (estimated)
-
Could a monthly shot replace weekly diabetes injections?
Disease control Not yet recruitingThis study tests whether people with type 2 diabetes can switch from a weekly injection of dulaglutide to a once-monthly shot called PG-102. The trial involves 60 adults whose blood sugar is well-controlled on dulaglutide. Researchers will compare blood sugar levels and safety ov…
Phase 2 • Sponsor: ProGen. Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New diabetes shot aims to beat semaglutide in early trial
Disease control Not yet recruitingThis Phase 2 study tests an experimental drug called PG-102, given as a weekly injection, in 80 adults with type 2 diabetes. Participants will receive either PG-102, a placebo, or the approved drug semaglutide for 24 weeks. The main goal is to see how well PG-102 lowers blood sug…
Phase 2 • Sponsor: ProGen. Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC